Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
3
Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us
4
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
5